calcium (±)-bis[4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate]
calcium (±)-bis[4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate] Basic information
- Product Name:
- calcium (±)-bis[4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate]
- Synonyms:
-
- calcium (±)-bis[4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate]
- Calcium (1)-bis(4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate)
- Einecs 285-313-2
- Proglumide hemicalcium
- CAS:
- 85068-56-0
- MF:
- C36H50CaN4O8
- MW:
- 706.8822
- EINECS:
- 285-313-2
- Mol File:
- 85068-56-0.mol
calcium (±)-bis[4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate] Usage And Synthesis
Uses
Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities[1][2][3][4][5].
in vivo
Proglumide (250-750 mg/kg; intraperitoneal injection; adult male Sprague Dawley rats) treatment is significantly effective in ameliorating the seizure activities, cognitive dysfunctions, and cerebral oxidative stress[1].
| Animal Model: | Adult male Sprague Dawley rats (200-250?g; 2 months old) are induced status epilepticus (SE)[1] |
| Dosage: | 250 mg/kg, 500 mg/kg, and 750?mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Dose-dependently and significantly increased the latencies to seizure and SE. Significantly and dose-dependently attenuated Li-PC (SE) induced increase in thiobarbituric acid (TBARS) and catalase (CAT), attenuated Li-Pc induced decrease in SOD, and attenuated depletion of GSH and glutathione-S transferase (GST) in the hippocampus and striatum. |
References
[1] Ahmad M, et al. The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus. Oxid Med Cell Longev. 2014;2014:630509. DOI:10.1155/2014/630509
[2] Iwamoto Y, et al. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. Gastroenterol Jpn. 1984 Feb;19(1):53-8. DOI:10.1007/BF02774646
[3] González-Puga C, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res. 2005 Oct;39(3):243-50. DOI:10.1111/j.1600-079X.2005.00239.x
[4] Bunney BS, et al. Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. Ann N Y Acad Sci. 1985;448:345-51. DOI:10.1111/j.1749-6632.1985.tb29929.x
[5] Tariq M, et al. Gastric and duodenal antiulcer and cytoprotective effects of proglumide in rats. J Pharmacol Exp Ther. 1987 May;241(2):602-7. PMID:3572816
calcium (±)-bis[4-(benzoylamino)-5-(dipropylamino)-5-oxovalerate]Supplier
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 010-60605840 15801484223;
- psaitong@jm-bio.com
- Tel
- 18024082417
- market@ubiochem.com
- Tel
- 15002134094
- marketing@targetmol.cn